#Japan #Tokyo #Liquid Biopsy #SOPHiA GENETICS #ADAM Innovations

A.D.A.M. Innovations and SOPHiA GENETICS Collaborate for Precision Oncology in Japan

In a significant development for precision oncology in Japan, A.D.A.M. Innovations, a leading private genetic testing company, has formed a strategic alliance with SOPHiA GENETICS, a pioneering AI-based health technology firm. The announcement was made during the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, signaling a major advancement in liquid biopsy testing and companion diagnostics aimed at improving cancer care for Japanese patients.

A.D.A.M. Innovations, with over 20 years of experience in the genetic testing field and more than 2.8 million genomic tests conducted, is known for its cutting-edge services. Located in the heart of Tokyo, the company has been at the forefront of introducing global innovations to Japan. By integrating the SOPHiA DDM™ platform, which is powered by artificial intelligence, A.D.A.M. Innovations plans to propel personalized cancer screening across the nation.

Objectives of the Partnership

The initial focus of this partnership is the launch of the innovative MSK-ACCESS® liquid biopsy application, driven by SOPHiA DDM™. This test is designed to identify actionable genomic alterations from a single blood draw, utilizing advanced AI algorithms to analyze cell-free circulating tumor DNA (ctDNA) non-invasively. The method employs a paired tumor-normal approach, enhancing accuracy while minimizing false positives. By localizing the test and analyzing samples in-house, A.D.A.M. Innovations aims to expedite turnaround times, reduce patient costs, and encourage local cancer research initiatives.

In addition to this, both companies aim to develop a liquid biopsy companion diagnostic (CDx) test within Japan. This transformation into a CDx will allow a broader patient base to benefit from high-quality tumor profiling tests, ultimately advancing personalized healthcare on a larger scale. Such innovations will also provide pharmaceutical partners with a powerful tool for expediting drug development and gaining entry into the Japanese market.

Remarks from Leadership

Ross Muken, President of SOPHiA GENETICS, emphasized the importance of making precision oncology more accessible to patients in Japan. He stated, “By combining A.D.A.M. Innovations’ extensive clinical expertise and local presence with the global reach of the SOPHiA DDM™ platform, we can drive nationwide adoption of data-driven medicine, enhancing both clinical research and personalized oncology care.”

Michel Mommejat, President of A.D.A.M. Innovations, echoed this sentiment, stating, “For over two decades, we have supported academic, research, and medical institutions with advanced genomic testing. Our collaboration with SOPHiA GENETICS and its AI-driven platform marks a substantial step forward in accelerating precision oncology throughout Japan. Local testing can speed up turnaround times, reduce costs, improve patient care, and support the rollout of CDx on a global scale.”

Commitment to Innovation

The partnership highlights a mutual commitment from both firms to advance data-driven solutions and liquid biopsy applications for cancer treatment in Japan. Those interested in learning more about these developments can visit A.D.A.M. Innovations and SOPHiA GENETICS at booth 2039 at the ESMO Congress from October 17-21, 2025.

For further details about SOPHiA GENETICS, please visit SOPHiAGENETICS.COM or connect on LinkedIn. For information on A.D.A.M. Innovations, check out ADAM-INNOVATIONS.COM or LinkedIn.

Conclusion

As the landscape of oncology continues to evolve with technological advancements, the collaboration between A.D.A.M. Innovations and SOPHiA GENETICS undeniably paves the way for enhanced cancer diagnostics and treatment frameworks in Japan, bringing hope to countless patients.